*/
Lev Gerlovin, Ezra Josephson | Life Sciences
Let’s say interchangeability is a viable regulatory option for manufacturers of biosimilars. Would it always make sense to seek an interchangeability designation from a strategic perspective? Because of the diversity and complexity of product and manufacturer characteristics, there may not be a single optimal strategy, but rather a continuum. Click below to read the article.
Dr. Annabelle Fowler featured in ERE spotlight series
The feature highlights Dr. Fowler’s path to becoming an expert witness, her approach to solving complex problems, and what she enjoys most about her work....